Pet Drug Reports

Reported signs

Reported sign · VeDDRA term

Lack of efficacy (endoparasite) - hookworm: reports listing this term

In plain language: the product did not have the expected effect: hookworms

49,844reports listing the term, 1987–20263.7% of all reports
4,482reports, 12 months to March 20263,512 in the 12 months before
51.2%classed serious, as reportedall reports: 38.6%
99.5%of these reports concern dogscat 0.5%

"Lack of efficacy (endoparasite) - hookworm" (the product did not have the expected effect: hookworms) is a coded term listed in 49,844 adverse event reports received by FDA, 3.7% of the database. Terms come from VeDDRA, the veterinary dictionary that FDA and drug companies use to code what a reporter describes.

4,482 reports listed it in the 12 months to March 2026, up 28% from 3,512 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases.

By active ingredient, the drugs named most often in those reports are ivermectin + pyrantel pamoate, moxidectin and pyrantel pamoate + sarolaner. That order mostly follows how many reports each has overall; the table gives the term's share within each drug's own reports as well.

99.5% of the reports concern dogs, 0.5% of the reports concern cats and 0% of the reports concern cattle. Of reports listing this term that state seriousness, 51.2% were classed as serious; 0.5% record a death or euthanasia among the outcomes.

Drugs named most often in these reports, by active ingredient

Active ingredients recorded for the drugReports listing the termShare of that drug's own reports
Ivermectin + Pyrantel Pamoate25,12615.5%
Moxidectin4,2037.3%
Pyrantel Pamoate + Sarolaner4,1928.1%
Lufenuron + Milbemycin Oxime3,04511.1%
Milbemycin Oxime + Spinosad2,9772.1%
Milbemycin Oxime2,3697.3%
Milbemycin Oxime + Praziquantel2,3447.1%
Selamectin1,7782.9%
Afoxolaner + Moxidectin + Pyrantel Pamoate87610%
Ivermectin + Praziquantel + Pyrantel Pamoate8359.3%
Lufenuron + Milbemycin Oxime + Praziquantel6599.8%
Lufenuron + Praziquantel54415.4%
Pyrantel Pamoate4287.3%
Imidacloprid + Moxidectin3911.7%
Febantel + Praziquantel + Pyrantel Pamoate3645.2%
Afoxolaner3540.6%
Fenbendazole3107.3%
Lotilaner2452.2%
Fluralaner1580.2%
Ivermectin1570.8%
Sarolaner1110.6%
Lotilaner + Moxidectin + Praziquantel + Pyrantel Pamoate1004.4%
Carprofen800.2%
Praziquantel + Pyrantel Pamoate771.5%
Oxibendazole744.3%

Ordered by number of reports, which mostly tracks how many reports a drug has overall. Across the whole database the term appears in 3.7% of reports. A drug's presence in a report means the animal received it, not that it produced the sign; FDA states that these data cannot be used to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Single ingredients, pooled across combinations

Active ingredientReports listing the termShare of the ingredient's own reports
Pyrantel Pamoate31,83312.7%
Ivermectin26,11313.4%
Milbemycin Oxime11,2944.8%
Moxidectin5,5865.8%
Praziquantel4,7825.7%
Sarolaner4,3795.5%
Lufenuron4,23310.7%
Spinosad2,9881.4%
Selamectin1,8122.5%
Afoxolaner1,2261.8%
Imidacloprid4251.5%
Febantel3655.1%
Lotilaner3332.5%
Fenbendazole3127.3%
Fluralaner1620.2%
Carprofen800.2%
Oxibendazole744.3%
Oclacitinib720.2%
Metronidazole671.9%
Prednisone440.5%
Gabapentin360.3%
Doxycycline300.7%
Maropitant290.2%
Levothyroxine sodium280.9%
Tramadol260.7%

Species split

Dog99.5%49,593
Cat0.5%236
Other0%5
Cougar0%1
Deer0%1

Coloured bar: share of reports listing this term. Grey bar: the species' share of all reports. The term appears in 5% of all dog reports; The term appears in 0.2% of all cat reports.

Trend

0243485Apr 2021: 257May 2021: 388Jun 2021: 396Jul 2021: 467Aug 2021: 394Sep 2021: 382Oct 2021: 334Nov 2021: 337Dec 2021: 232Jan 2022: 2192022Feb 2022: 233Mar 2022: 330Apr 2022: 391May 2022: 450Jun 2022: 287Jul 2022: 272Aug 2022: 382Sep 2022: 315Oct 2022: 353Nov 2022: 291Dec 2022: 222Jan 2023: 2412023Feb 2023: 236Mar 2023: 270Apr 2023: 317May 2023: 410Jun 2023: 366Jul 2023: 304Aug 2023: 375Sep 2023: 301Oct 2023: 385Nov 2023: 282Dec 2023: 147Jan 2024: 1852024Feb 2024: 215Mar 2024: 266Apr 2024: 389May 2024: 372Jun 2024: 350Jul 2024: 351Aug 2024: 333Sep 2024: 315Oct 2024: 284Nov 2024: 232Dec 2024: 194Jan 2025: 2362025Feb 2025: 218Mar 2025: 238Apr 2025: 449May 2025: 485Jun 2025: 478Jul 2025: 484Aug 2025: 436Sep 2025: 425Oct 2025: 404Nov 2025: 326Dec 2025: 245Jan 2026: 2632026Feb 2026: 246Mar 2026: 241

Reports by month FDA received them, five years to March 2026. The newest months are incomplete because FDA posts reports with a delay of three to six months.

02,2124,4241987: 719871988: 111989: 31990: 71991: 1119911992: 71993: 91994: 61995: 1119951996: 111997: 141998: 181999: 2219992000: 452001: 472002: 682003: 16020032004: 3392005: 5642006: 9042007: 1,75620072008: 1,9002009: 1,8902010: 1,7562011: 1,75920112012: 2,1622013: 2,9772014: 3,0512015: 3,42020152016: 3,8412017: 2,9322018: 142019: 620192020: 4972021: 3,5802022: 3,7452023: 3,63420232024: 3,4862025: 4,4242026: 750

Outcomes and ages in these reports

Outcome recorded in the report

Recovered/Normal4.6%2,307
Recovered with Sequela0.3%154
Ongoing24.1%11,988
Died0.4%204
Euthanized0.1%30
Outcome Unknown48.6%24,212

Age of the animal

Under 1 year9.7%4,854
1 to 3 years37.7%18,784
4 to 7 years27.8%13,846
8 to 11 years15.8%7,889
12 years and over5%2,503
Age not given3.9%1,968
MeasureReports listing this termAll reports
Reports49,8441,357,245
Classed serious, of reports stating it51.2%38.6%
Death or euthanasia recorded, per 1,000 reports4.763.8

Grey bars and the right-hand column are the whole database. Outcomes are as stated by the reporter and describe the report as a whole, not this term alone.

Questions about "Lack of efficacy (endoparasite) - hookworm"

What does "Lack of efficacy (endoparasite) - hookworm" mean in an adverse event report?

In plain language: the product did not have the expected effect: hookworms. It is a VeDDRA dictionary term picked to code what the reporter described. The report's free-text description is not published by FDA and is not shown here.

How many reports list lack of efficacy (endoparasite) - hookworm?

49,844 reports through March 2026 (3.7% of all reports), 4,482 of them in the latest 12 months.

Which drugs are named most often alongside this term?

By active ingredient: ivermectin + pyrantel pamoate (25,126), moxidectin (4,203), pyrantel pamoate + sarolaner (4,192), lufenuron + milbemycin oxime (3,045) and milbemycin oxime + spinosad (2,977). Drugs with many reports overall lead almost every term's list. Brands cannot be identified: openFDA masks them.

Which species are involved?

dog (99.5%), cat (0.5%), cattle (0%) and other (0%).

Does a drug appearing here mean it produced this sign?

No such conclusion can be drawn. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources."

My animal shows this sign. What now?

This site cannot assess an animal. A veterinarian can; for an emergency, contact a veterinary emergency clinic. See the guide on when to call a vet.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 30 Sep 2026. Spelling variants of the same VeDDRA term (for example with and without a cross-reference note) are pooled. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.